Skip to main content
Top
Published in: Clinical Rheumatology 1/2024

Open Access 28-08-2023 | Inflammatory Rheumatic Diseases | BRIEF REPORT

Inflammatory rheumatic diseases and the risk of drug use disorders: a register-based cohort study in Sweden

Authors: Ali Kiadaliri, Andrea Dell’Isola, Martin Englund

Published in: Clinical Rheumatology | Issue 1/2024

Login to get access

Abstract

To investigate the association between chronic inflammatory rheumatic diseases (CIRD) and drug use disorder (DUD). Individuals aged ≥ 30 years in 2009 that met the following conditions were included: residing in the Skåne region, Sweden, with at least one healthcare contact in person and no history of DUD (ICD-10 codes F11-F16, F18-F19) during 1998–2009 (N = 649,891). CIRD was defined as the presence of rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or systemic lupus erythematosus. Treating CIRD as a time-varying exposure, we followed people from January 1, 2010 until a diagnosis of DUD, death, relocation outside the region, or December 31, 2019, whichever occurred first. We used flexible parametric survival models adjusted for attained age, sociodemographic characteristics, and coexisting conditions for data analysis. There were 64 (95% CI 62–66) and 104 (88–123) incident DUD per 100,000 person-years among those without and with CIRD, respectively. CIRD was associated with an increased risk of DUD in age-adjusted analysis (hazard ratio [HR] 1.77, 95% CI 1.49–2.09). Almost identical HR (1.71, 95% CI 1.45–2.03) was estimated after adjustment for sociodemographic characteristics, and it slightly attenuated when coexisting conditions were additionally accounted for (1.47, 95% CI 1.24–1.74). Fully adjusted HRs were 1.49 (1.21–1.85) for RA, 2.00 (1.38–2.90) for AS, and 1.58 (1.16–2.16) for PsA. More stringent definitions of CIRD didn’t alter our findings. CIRD was associated with an increased risk of DUD independent of sociodemographic factors and coexisting conditions.
Key Points
A register-based cohort study including 649,891 individuals aged≥30 residing in the Skåne region, Sweden, was conducted.
Chronic inflammatory rheumatic diseases were associated with higher risks of drug use disorder independent of sociodemographic factors and coexisting conditions.
Appendix
Available only for authorised users
Literature
2.
go back to reference Bergman MJ (2006) Social and economic impact of inflammatory arthritis. Postgrad Med 119:5–11 Bergman MJ (2006) Social and economic impact of inflammatory arthritis. Postgrad Med 119:5–11
11.
go back to reference Royston P, Lambert PC (2011) Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model. Stata Press, College Station, TX, USA Royston P, Lambert PC (2011) Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model. Stata Press, College Station, TX, USA
Metadata
Title
Inflammatory rheumatic diseases and the risk of drug use disorders: a register-based cohort study in Sweden
Authors
Ali Kiadaliri
Andrea Dell’Isola
Martin Englund
Publication date
28-08-2023
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 1/2024
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-023-06755-w

Other articles of this Issue 1/2024

Clinical Rheumatology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.